Selection of intracellular single-domain antibodies targeting the HIV-1 Vpr protein by cytoplasmic yeast two-hybrid system

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Matz, Julie ^a,b,c,d   Hérate, Cécile ^d,e,f   Bouchet, Jérôme ^d,e,f   Dusetti, Nelson ^a,b,c,d   Gayet, Odile ^a,b,c,d   Baty, Daniel ^a,b,c,d   Benichou, Serge ^d,e,f   Chames, Patrick ^a,b,c,d  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d CNRS   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f INSTITUT COCHIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; NANOBODY; VPR PROTEIN; PROTEIN BINDING; VPR PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIGEN BINDING; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DRUG PURIFICATION; ESCHERICHIA COLI; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOFLUORESCENCE; IN VIVO STUDY; NONHUMAN; PROTEIN BINDING; PROTEIN TARGETING; TWO HYBRID SYSTEM; VIRUS CAPSID; YEAST; GENETIC TRANSFECTION; HELA CELL LINE; HUMAN; IMMUNOLOGY; METABOLISM; SACCHAROMYCES CEREVISIAE;

EUKARYOTA; HUMAN IMMUNODEFICIENCY VIRUS 1; LAMA (MAMMAL);

CELL NUCLEUS; CYTOPLASM; HELA CELLS; HIV-1; HUMANS; PROTEIN BINDING; SACCHAROMYCES CEREVISIAE; SINGLE-DOMAIN ANTIBODIES; TRANSFECTION; TWO-HYBRID SYSTEM TECHNIQUES; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84918825195     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113729     Document Type: Article

References (42)

1. Kwong PD, Mascola JR, Nabel GJ (2011) Rational Design of Vaccines to Elicit Broadly Neutralizing Antibodies to HIV-1. Cold Spring Harb Perspect Med 1: a007278.
2. Ghosh RK, Ghosh SM, Chawla S (2011) Recent advances in antiretroviral drugs. Expert Opin Pharmacother 12: 31-46.
3. Foster JL, Garcia JV (2008) HIV-1 Nef: at the crossroads. Retrovirology 5: 84.
4. Barbas CF 3rd, Bjorling E, Chiodi F, Dunlop N, Cababa D, et al. (1992) Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci U S A 89: 9339-9343.
5. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, et al. (2011) Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333: 1633-1637.
6. Worn A, Auf der Maur A, Escher D, Honegger A, Barberis A, et al. (2000) Correlation between in vitro stability and in vivo performance of anti-GCN4 intrabodies as cytoplasmic inhibitors. J Biol Chem 275: 2795-2803.
7. Mhashilkar AM, LaVecchio J, Eberhardt B, Porter-Brooks J, Boisot S, et al. (1999) Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies. Hum Gene Ther 10: 1453-1467.
8. Levin R, Mhashilkar AM, Dorfman T, Bukovsky A, Zani C, et al. (1997) Inhibition of early and late events of the HIV-1 replication cycle by cytoplasmic Fab intrabodies against the matrix protein, p17. Mol Med 3: 96-110.
9. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, et al. (1993) Naturally occurring antibodies devoid of light chains. Nature 363: 446-448.
10. Desmyter A, Transue TR, Ghahroudi MA, Thi MH, Poortmans F, et al. (1996) Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat Struct Biol 3: 803-811.
11. Muyldermans S (2001) Single domain camel antibodies: current status. J Biotechnol 74: 277-302.
12. Van Impe K, Bethuyne J, Cool S, Impens F, Ruano-Gallego D, et al. (2013) A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis. Breast Cancer Res 15: R116.
13. Staus DP, Wingler LM, Strachan RT, Rasmussen SG, Pardon E, et al. (2014) Regulation of beta2-adrenergic receptor function by conformationally selective single-domain intrabodies. Mol Pharmacol 85: 472-481.
14. Vercruysse T, Boons E, Venken T, Vanstreels E, Voet A, et al. (2013) Mapping the binding interface between an HIV-1 inhibiting intrabody and the viral protein Rev. PLoS One 8: e60259.
15. Irannejad R, Tomshine JC, Tomshine JR, Chevalier M, Mahoney JP, et al. (2013) Conformational biosensors reveal GPCR signalling from endosomes. Nature 495: 534-538.
16. Alzogaray V, Danquah W, Aguirre A, Urrutia M, Berguer P, et al. (2011) Single-domain llama antibodies as specific intracellular inhibitors of SpvB, the actin ADP-ribosylating toxin of Salmonella typhimurium. FASEB J 25: 526-534.
17. De Clercq S, Zwaenepoel O, Martens E, Vandekerckhove J, Guillabert A, et al. (2013) Nanobody-induced perturbation of LFA-1/L-plastin phosphorylation impairs MTOC docking, immune synapse formation and T cell activation. Cell Mol Life Sci 70: 909-922.
18. Bouchet J, Basmaciogullari SE, Chrobak P, Stolp B, Bouchard N, et al. (2011) Inhibition of the Nef regulatory protein of HIV-1 by a single-domain antibody. Blood 117: 3559-3568.
19. Vercruysse T, Pardon E, Vanstreels E, Steyaert J, Daelemans D (2010) An intrabody based on a llama single-domain antibody targeting the N-terminal alpha-helical multimerization domain of HIV-1 rev prevents viral production. J Biol Chem 285: 21768-21780.
20. Visintin M, Tse E, Axelson H, Rabbitts TH, Cattaneo A (1999) Selection of antibodies for intracellular function using a two-hybrid in vivo system. Proc Natl Acad Sci U S A 96: 11723-11728.
21. Tanaka T, Lobato MN, Rabbitts TH (2003) Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies. J Mol Biol 331: 1109-1120.
22. Fields S, Song O (1989) A novel genetic system to detect protein-protein interactions. Nature 340: 245-246.
23. Allen JB, Walberg MW, Edwards MC, Elledge SJ (1995) Finding prospective partners in the library: the two-hybrid system and phage display find a match. Trends Biochem Sci 20: 511-516.
24. Aronheim A, Zandi E, Hennemann H, Elledge SJ, Karin M (1997) Isolation of an AP-1 repressor by a novel method for detecting protein-protein interactions. Mol Cell Biol 17: 3094-3102.
25. Le Rouzic E, Benichou S (2005) The Vpr protein from HIV-1: distinct roles along the viral life cycle. Retrovirology 2: 11.
26. Romani B, Engelbrecht S (2009) Human immunodeficiency virus type 1 Vpr: functions and molecular interactions. J Gen Virol 90: 1795-1805.
27. Freed EO (1998) HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 251: 1-15.
28. Arhel N (2010) Revisiting HIV-1 uncoating. Retrovirology 7: 96.
29. Behar G, Chames P, Teulon I, Cornillon A, Alshoukr F, et al. (2009) Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen. FEBS J 276: 3881-3893.
30. Matz J, Kessler P, Bouchet J, Combes O, Ramos OH, et al. (2013) Straightforward Selection of Broadly Neutralizing Single-Domain Antibodies Targeting the Conserved CD4 and Coreceptor Binding Sites of HIV-1 gp120. J Virol 87: 1137-1149.
31. Seillier M, Peuget S, Gayet O, Gauthier C, N'Guessan P, et al. (2012) TP53INP1, a tumor suppressor, interacts with LC3 and ATG8-family proteins through the LC3-interacting region (LIR) and promotes autophagy-dependent cell death. Cell Death Differ.
32. Depienne C, Roques P, Creminon C, Fritsch L, Casseron R, et al. (2000) Cellular distribution and karyophilic properties of matrix, integrase, and Vpr proteins from the human and simian immunodeficiency viruses. Exp Cell Res 260: 387-395.
33. Jacquot G, Le Rouzic E, Maidou-Peindara P, Maizy M, Lefrere JJ, et al. (2009) Characterization of the molecular determinants of primary HIV-1 Vpr proteins: impact of the Q65R and R77Q substitutions on Vpr functions. PLoS One 4: e7514.
34. Dean PN, Jett JH (1974) Mathematical analysis of DNA distributions derived from flow microfluorometry. J Cell Biol 60: 523-527.
35. Guenzel CA, Herate C, Benichou S (2014) HIV-1 Vpr-a still "enigmatic multitasker". Front Microbiol 5: 127.
36. Bouchet J, Herate C, Guenzel C, Verollet C, Jarviluoma A, et al. (2012) Single-domain antibody-SH3 fusions for efficient neutralization of HIV-1 Nef functions. J Virol.
37. Jarviluoma A, Strandin T, Lulf S, Bouchet J, Makela AR, et al. (2012) High-affinity target binding engineered via fusion of a single-domain antibody fragment with a ligand-tailored SH3 domain. PLoS One 7: e40331.
38. Krichevsky A, Graessmann A, Nissim A, Piller SC, Zakai N, et al. (2003) Antibody fragments selected by phage display against the nuclear localization signal of the HIV-1 Vpr protein inhibit nuclear import in permeabilized and intact cultured cells. Virology 305: 77-92.
39. Vielemeyer O, Nizak C, Jimenez AJ, Echard A, Goud B, et al. (2010) Characterization of single chain antibody targets through yeast two hybrid. BMC Biotechnol 10: 59.
40. Mukhtar MM, Li S, Li W, Wan T, Mu Y, et al. (2009) Single-chain intracellular antibodies inhibit influenza virus replication by disrupting interaction of proteins involved in viral replication and transcription. Int J Biochem Cell Biol 41: 554-560.
41. Fu X, Gao X, He S, Huang D, Zhang P, et al. (2013) Design and selection of a camelid single-chain antibody yeast two-hybrid library produced de novo for the cap protein of porcine circovirus type 2 (PCV2). PLoS One 8: e56222.
42. Pellis M, Pardon E, Zolghadr K, Rothbauer U, Vincke C, et al. (2012) A bacterial-two-hybrid selection system for one-step isolation of intracellularly functional Nanobodies. Arch Biochem Biophys 526: 114-123.